# Encompass Health announces date of 2026 second quarter earnings call
Canonical URL: https://biopharmsignal.com/news/EHC/encompass-health-announces-date-of-2026-second-quarter-earnings-call-6ef36947
Ticker: EHC
Company: Encompass Health Corporation
Source: Encompass Health Corporation
Published: 2026-06-30 20:30 EST
Original Source URL: https://investor.encompasshealth.com/news/news-details/2026/Encompass-Health-announces-date-of-2026-second-quarter-earnings-call/default.aspx
## Summary

Encompass Health Corp. (NYSE: EHC) today announced it will report results for its second quarter ended June 30, 2026, after the market closes on Wednesday, Aug. 5, 2026. The Company will host an investor conference call at 10 a.m. ET on Thursday, Aug. 6, 2026, to discuss its results. The conference call may be accessed by dialing 833-354-6854 and providing the conference ID EHCQ226. International callers should dial 785-838-9343 and provide the same conference ID. Please call approximately 10 minutes before the start of the call to ensure you are connected. A live webcast of the conference call and an online replay of the conference call can be found on the Company's investor website at investor.encompasshealth.com . About Encompass Health Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 176 hospitals in 39 states and Puerto Rico, the Company provides high-quality,

## Article Body
, /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will report results for its second quarter ended June 30, 2026, after the market closes on Wednesday, Aug. 5, 2026. The Company will host an investor conference call at 10 a.m. ET on Thursday, Aug. 6, 2026, to discuss its results.

The conference call may be accessed by dialing 833-354-6854 and providing the conference ID EHCQ226. International callers should dial 785-838-9343 and provide the same conference ID. Please call approximately 10 minutes before the start of the call to ensure you are connected.

A live webcast of the conference call and an online replay of the conference call can be found on the Company's investor website at investor.encompasshealth.com .

About Encompass Health Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 176 hospitals in 39 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from major injuries or illnesses, using advanced technology and innovative treatments to maximize recovery. Encompass Health is recognized by Newsweek as America's Most Awarded Leader in Inpatient Rehabilitation and is ranked among Fortune's World's Most Admired Companies™ and Forbes' America's Best Companies. It is also recognized by Becker's Healthcare and Modern Healthcare as a top healthcare employer. For more information, visit encompasshealth.com and follow us on our newsroom , X , Instagram and Facebook .

From Fortune.© 2026 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World's Most Admired Companies™ is a trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health.

Media contact: Polly Manuel | 205-970-5912 media@encompasshealth.com

Investor relations contact: Mark Miller | 205-970-5860 mark.miller@encompasshealth.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/encompass-health-announces-date-of-2026-second-quarter-earnings-call-302822276.html

SOURCE Encompass Health Corp.
## Recent Company News
- 2026-06-30 20:30 EST — [Encompass Health announces date of 2026 second quarter earnings call](https://biopharmsignal.com/news/EHC/encompass-health-announces-date-of-2026-second-quarter-earnings-call-6ef36947) — Source: Encompass Health Corporation
- 2026-06-25 13:46 EST — [Eastside Rehabilitation Hospital now open in Georgia](https://biopharmsignal.com/news/EHC/eastside-rehabilitation-hospital-now-open-in-georgia) — Source: Encompass Health Corporation
- 2026-06-25 13:46 EST — [Encompass Health to build 36-bed inpatient rehabilitation hospital in Bridgeport, West Virginia](https://biopharmsignal.com/news/EHC/encompass-health-to-build-36-bed-inpatient-rehabilitation-hospital-in-bridgeport-west-virginia) — Source: Encompass Health Corporation
- 2026-06-25 13:46 EST — [Encompass Health issues notice for partial redemption of its 4.500% senior notes due 2028](https://biopharmsignal.com/news/EHC/encompass-health-issues-notice-for-partial-redemption-of-its-4-500-senior-notes-due-2028) — Source: Encompass Health Corporation
- 2026-06-25 13:46 EST — [Encompass Health announces pricing of $500 million of senior notes due 2034 in a private offering](https://biopharmsignal.com/news/EHC/encompass-health-announces-pricing-of-500-million-of-senior-notes-due-2034-in-a-private-offering) — Source: Encompass Health Corporation
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)